External traditional Chinese medicine composition for treating convalescence of community-acquired pneumonia and application of external traditional Chinese medicine composition

Abstract

The invention relates to an external traditional Chinese medicine composition for treating community-acquired pneumonia in a convalescence period. The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 28-32 parts of raw astragalus membranaceus, 13-17 parts of roasted rhizoma atractylodis macrocephalae, 10-14 parts of angelica sinensis, 7-11 parts of rhizoma acori graminei, 4-8 parts of folium artemisiae argyi, 7-11 parts of peach kernels, 4-8 parts of almonds, 7-11 parts of salvia miltiorrhiza and 4-8 parts of agastache rugosus. The invention further provides application of the traditional Chinese medicine composition. The traditional Chinese medicine is mainly used for treating lung-spleen qi deficiency syndrome; the medicine has the effects of tonifying lung and spleen, resolving dampness and dredging collaterals. Astragalus mongholicus in the formula is sweet and warm, can tonify qi of spleen and lung internally and strengthen exterior externally, and is a monarch drug. The Chinese angelica is used for activating blood and harmonizing ying, treating adverse cough and qi and moistening lung dryness, so that qi and blood are dependent and complement each other, and the Chinese angelica and the Chinese angelica are used as ministerial drugs. The peach kernel enters blood and is slightly used for removing blood stasis of blood collaterals; the almonds enter qi components and are slightly used for reducing lung qi from rising upside down. All the medicines are combined to support qi of the lung and spleen, strengthen the foundation, resolve dampness, dredge collaterals, clean residual evil and expel evil, so that qi and blood are biochemically active, and the concept of strengthening body resistance and eliminating evil is embodied.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of traditional Chinese medicine, in particular to a kind of external use traditional Chinese medicine composition for treating community-acquired pneumonia recovery period and application thereof. BACKGROUND

[0002] Community acquired pneumonia (CAP) refers to the infection of lung parenchyma (including alveolar wall, i.e. the broad sense of lung interstitium) inflammation outside the hospital, including the infection of pathogen with clear incubation period and the onset of pneumonia within the average incubation period after admission, which is one of the common infectious diseases threatening the health of the population.

[0003] The diagnostic criteria for community-acquired pneumonia recovery period are as follows: (1) body temperature returns to normal for more than 3 days; (2) respiratory symptoms improve significantly; (3) lung imaging shows that exudative lesions improve significantly; (4) heart rate ≤100 times / min at rest, respiratory rate ≤24 times / min at rest, and systolic blood pressure ≥90 mmHg; (5) under non-oxygen condition, arterial oxygen saturation is normal.

[0004] Chinese patent document CN117257866A discloses a traditional Chinese medicine composition for treating community-acquired pneumonia, which is made of raw medicinal materials in the following proportions by weight: Kaijinlao 26-34 parts, Sangbaipi 5-13 parts, Shengmaohuang 4-8 parts, Kuaxingren 5-13 parts, Shengshigao 26-34 parts, Chaihu 5-13 parts, Huangqi 5-13 parts, Shengdahuang 4-8 parts, Shenggancao 5-13 parts. The application also provides the use of the traditional Chinese medicine composition. The advantages of the application are as follows: the application adopts the treatment principle of relieving lung and dredging bowels and resolving, takes Shengmaohuang as the monarch drug to expel evil heat from the lung; Shengshigao, Sangbaipi, Shengdahuang and Jinqimai as the ministerial drugs to clear lung heat without leaving evil, transform phlegm and make the lung qi descend; Chaihu, Huangqi and Kuaxingren as the auxiliary drugs to soothe liver fire and prevent the liver from attacking the lung, which embodies the thought of “preventing disease” in traditional Chinese medicine; and Shenggancao as the ministerial drug to tonify qi and harmonize the center and regulate all drugs.

[0005] Chinese patent document CN 118576648AA discloses a traditional Chinese medicine composition for treating community-acquired pneumonia, which is made of the following raw medicinal materials by weight: apricot kernel 3-9 parts, raw gypsum 10-30 parts, gualou 10-30 parts, raw ephedra 1-6 parts, fried ephedra 1-6 parts, tianlai zi 5-15 parts, peach kernel 3-10 parts, raw rhubarb 1-6 parts, honeysuckle 3-10 parts, forsythia 3-10 parts, green wormwood 6-15 parts. The traditional Chinese medicine composition can significantly improve the early and middle clinical symptoms of community-acquired pneumonia, promote the absorption of lung inflammation in a short period of time, has a tendency to reduce and improve the occurrence of severe pneumonia, has a significant effect, and has good clinical application value. The traditional Chinese medicine composition can be made into a decoction, granules, tablets, capsules or oral liquid by a conventional method, has good prepared medicine property, high safety, and is suitable for development into a new traditional Chinese medicine.

[0006] Such traditional Chinese medicine compositions for treating community-acquired pneumonia have the following disadvantages: too many medicinal materials, difficult to obtain, expensive; not obvious in medicinal effect, poor treatment effect, etc. Therefore, there is an urgent need for a traditional Chinese medicine composition for treating the recovery period of community-acquired pneumonia, which has obvious effect, few medicinal materials, practical operability, high compliance, safety and effectiveness. SUMMARY

[0007] The purpose of the present application is to overcome the deficiencies in the prior art, and to provide a traditional Chinese medicine composition for treating the recovery period of community-acquired pneumonia and its application.

[0008] In a first aspect, the present application provides a traditional Chinese medicine composition for treating the recovery period of community-acquired pneumonia, which is made of the following raw medicinal materials by weight: raw radix astragali 28-32 parts, fried radix atractylodis 13-17 parts, angelica 10-14 parts, atractylodes rhizome 7-11 parts, mugwort leaf 4-8 parts, peach kernel 7-11 parts, apricot kernel 4-8 parts, salvia miltiorrhiza 7-11 parts, agastache 4-8 parts.

[0009] As a preferred example, the traditional Chinese medicine composition is made of the following raw medicinal materials by weight: raw radix astragali 29-31 parts, fried radix atractylodis 14-16 parts, angelica 11-13 parts, atractylodes rhizome 8-10 parts, mugwort leaf 5-7 parts, peach kernel 8-10 parts, apricot kernel 5-7 parts, salvia miltiorrhiza 8-10 parts, agastache 5-7 parts.

[0010] As a preferred example, the traditional Chinese medicine composition is made of the following raw medicinal materials by weight: raw radix astragali 30 parts, fried radix atractylodis 15 parts, angelica 12 parts, atractylodes rhizome 9 parts, mugwort leaf 6 parts, peach kernel 9 parts, apricot kernel 6 parts, salvia miltiorrhiza 9 parts, agastache 6 parts.

[0011] As a preferred example, the traditional Chinese medicine composition is a traditional Chinese medicine sachet.

[0012] In a second aspect, the present application provides a pharmaceutical composition for treating community-acquired pneumonia recovery, which is composed of the traditional Chinese medicine composition and ambroxol hydrochloride.

[0013] In a third aspect, the present application provides an application of the traditional Chinese medicine composition in preparing a medicine for treating community-acquired pneumonia recovery.

[0014] In a fourth aspect, the present application provides an application of the pharmaceutical composition in preparing a medicine for treating community-acquired pneumonia recovery.

[0015] The traditional Chinese medicine composition in the present application is suitable for community-acquired pneumonia recovery, and the symptoms include cough, shortness of breath, fatigue, poor appetite, abdominal distension and spontaneous sweating.

[0016] The configuration method is as follows: first, the traditional Chinese medicine herbs are weighed according to the prescription ratio, cleaned, and dried at 60℃ in a high-temperature environment, and then the medicine is crushed to 100 meshes, and the traditional Chinese medicine powder is then divided into inner bags, with 3g of medicine in each bag, and then the inner bags are divided into sachet bags.

[0017] The use method is as follows: the traditional Chinese medicine sachet is placed in a high-frequency contact area of the main living space of the subject (such as an office area, a bedside or a pillow side, etc.), and the fragrance is volatilized after being kneaded.

[0018] The present application has the following advantages: the present application is mainly used for treating lung and spleen qi deficiency syndrome, and has the effects of tonifying lung and spleen, and removing dampness and dredging collaterals. Huangqi in the prescription is sweet and warm, and can tonify the qi of the spleen and lung, and is the monarch drug. Baizhu can benefit the qi and invigorate the spleen, and can be used with Danggui to activate blood and promote circulation, and can treat cough and reverse qi, and can moisten the dryness of the lung, so that the qi and blood are interdependent and complement each other, and are the ministerial drugs. Taoren enters the blood aspect and is used to remove blood stasis, and Xingren enters the qi aspect and is used to reduce the lung qi. The two drugs are used together, and one qi and one blood increase the effects of promoting blood circulation and removing blood stasis, and relieving cough and asthma. Danshen has a bitter taste and a cold nature, and is used to regulate the meridians, and is good at dredging and removing the remaining evil, and is the auxiliary drug. The nature of Eijiao is aromatic, and can dredge the twelve meridians, and warm the middle and remove cold, and remove the blood and the stagnation in the qi, so that the remaining evil has a smooth path, and the drugs are used together to support the qi of the lung and spleen, and remove dampness and dredge collaterals, and drive the evil out of the body, so that the qi and blood are generated and the concept of “supporting the healthy and removing the evil” is embodied. DETAILED DESCRIPTION

[0019] The present application will be further described in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present application and not to limit the scope of the present application. In addition, it should be understood that after reading the content described in the present application, those skilled in the art can make various modifications or changes to the present application, and these equivalent forms also fall within the scope defined by the claims of the present application.

[0020] Example 1 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0021] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0022] Example 2 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0023] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0024] Example 3 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0025] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0026] Example 4 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0027] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0028] Example 5 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0029] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0030] Example 6 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0031] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0032] Example 7 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0033] Radix Astragali 30 parts, Poria 15 parts, Angelica 12 parts, Acorus 9 parts, Folium Artemisiae Argyi 6 parts, Semen Persicae 9 parts, Semen Armeniacae Amarum 6 parts, Salvia 9 parts, Agastache 6 parts.

[0034] Example 8 External use of traditional Chinese medicine composition for treating recovery period of community-acquired pneumonia

[0035] Radix Astragali 29 parts, fried Atractylodes 13 parts, Angelica 14 parts, Acorus 9 parts, wormwood leaves 5 parts, peach kernel 10 parts, apricot kernel 4 parts, Salvia 11 parts, Agastache 6 parts.

[0036] Example 9 External use of traditional Chinese medicine composition for treating community-acquired pneumonia recovery period (nine)

[0037] Radix Astragali 31 parts, fried Atractylodes 17 parts, Angelica 12 parts, Acorus 8 parts, wormwood leaves 7 parts, peach kernel 7 parts, apricot kernel 8 parts, Salvia 9 parts, Agastache 5 parts.

[0038] Example 10 External use of traditional Chinese medicine composition for treating community-acquired pneumonia recovery period (ten)

[0039] Radix Astragali 28 parts, fried Atractylodes 15 parts, Angelica 11 parts, Acorus 10 parts, wormwood leaves 4 parts, peach kernel 11 parts, apricot kernel 6 parts, Salvia 8 parts, Agastache 7 parts.

[0040] Example 11 External use of traditional Chinese medicine composition for treating community-acquired pneumonia recovery period (eleven)

[0041] Radix Astragali 32 parts, fried Atractylodes 14 parts, Angelica 13 parts, Acorus 7 parts, wormwood leaves 8 parts, peach kernel 9 parts, apricot kernel 5 parts, Salvia 10 parts, Agastache 4 parts.

[0042] Example 12 External use of traditional Chinese medicine composition for treating community-acquired pneumonia recovery period

[0043] Select Radix Astragali 30 parts, fried Atractylodes 15 parts, Angelica 12 parts, Acorus 9 parts, wormwood leaves 6 parts, peach kernel 9 parts, apricot kernel 6 parts, Salvia 9 parts, Agastache 6 parts, according to the proportion into powder, pass through 100 mesh screen, pack 3g per bag in non-harm paper inner bag, seal and store, put into the size of 7*10cm sachet outer bag. Wear on the chest during the day, put on the pillow at night, replace the sachet once a week.

[0044] Example 13 Clinical efficacy experiment

[0045] 1. Data and methods

[0046] 1.1 Case selection According to the Chinese Medical Association Respiratory Branch's "Chinese Adult Community-acquired Pneumonia Diagnosis and Treatment Guidelines (2016 Edition)", non-severe recovery period of community-acquired pneumonia, western medicine diagnostic criteria and "Community-acquired Pneumonia Diagnosis and Treatment Guidelines" (2018 revised edition) of traditional Chinese medicine diagnostic criteria, traditional Chinese medicine syndrome belongs to lung and spleen qi deficiency; Age range is 20-75 years old; Patients' informed consent, voluntary participation; Exclusion criteria: Age less than 20 years old or more than 75 years old; Those who are undergoing other clinical experiments; Those who have serious cardiovascular, cerebral vascular, liver, kidney, tumor and hematopoietic system diseases; Those with mental disorders; Those who are allergic to the research drug ingredients.

[0047] 1.2 Clinical data Selection of patients with community-acquired pneumonia, non-severe convalescent period, and TCM syndrome of lung and spleen qi deficiency from March 2024 to March 2025 in the outpatient department of Shanghai Jing'an District Hospital of Traditional Chinese Medicine. According to the principle of complete randomization, 36 cases in the control group and 36 cases in the treatment group. There was no significant difference in gender, age, and presence or absence of underlying diseases between the two groups (P>0.05), as shown in Table 1.

[0048]

[0049] 1.3 Treatment regimen

[0050] (1) General treatment: Patients with pneumonia recovery period related knowledge, give health education, dietary advice, pay attention to keep warm.

[0051] (2) Control group: According to the diagnosis and treatment of Chinese adult community-acquired pneumonia diagnosis and treatment guidelines (2016 edition), oral: hydrochloric acid ambroxol capsule (production enterprise: Shanghai Xinyi Tianping Pharmaceutical Co., Ltd., batch number: national drug standard word: H20000282, specification: 30mg*30 / box), usage: three times a day, one grain a day, oral after meal; If blood routine test suggests that the inflammatory index increases before treatment, add oral levofloxacin tablets (production enterprise: Zhejiang Puli Pharmaceutical Co., Ltd., batch number: national drug standard word: H20213082, specification: 0.25g*30 / box) usage: once a day, two tablets each time, oral.

[0052] (3) Treatment group: On the basis of the control group, add Chinese medicine sachet treatment, select 30 parts of Huangqi, 15 parts of fried Baishu, 12 parts of Danggui, 9 parts of Shichangpu, 6 parts of Eiyeh, 9 parts of Taoren, 6 parts of Xingren, 9 parts of Danshen, 6 parts of Huoxiang, according to the proportion, beat into powder, pass through 100 mesh sieve, pack into non-interference paper inner bag, 3g per bag, seal and store, put into 7*10cm sachet outer bag. Wear on the chest during the day, put beside the pillow at night, replace the sachet once a week.

[0053] 1.4 Treatment course: The treatment course of the treatment group and the control group is 2 weeks.

[0054] 1.5 Observation index

[0055] (1) TCM syndrome score: Compare the TCM syndrome score changes of the two groups before and after treatment. According to the clinical research guidelines for respiratory system diseases in the "Guiding Principles for Clinical Research of New Drugs of Traditional Chinese Medicine", the TCM clinical symptom score table is formulated, the symptoms are scored according to the severity, and the normal, mild, moderate and severe are scored respectively. Normal is 0 points, mild is 1 point, moderate is 2 points, and severe is 3 points. Evaluate the changes of cough, sputum, shortness of breath, fatigue, sweating, abdominal distension, poor appetite, lung auscultation, tongue and pulse, and descriptive record, not included in the score.

[0056] (2) Inflammatory markers: compare the changes in C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) levels before and after treatment in both groups.

[0057] (3) Coagulation function markers: compare the changes in fibrinogen (FDP) and D-Dimer (DDi) before and after treatment in both groups.

[0058] (4) Quality of life: assessed using the SF-36 quality of life questionnaire, which includes 8 dimensions: physical function, role-physical, bodily pain, general health, vitality, social functioning, emotional role, and mental health. The total score is the sum of the converted scores for each dimension (0-100 points), with higher scores indicating better quality of life.

[0059] (5) Recurrence: after completing the entire treatment, patients were followed up by telephone at 1 month, 3 months, and 6 months to assess recurrence.

[0060] (6) Safety markers: blood routine, stool routine, liver function, kidney function, body temperature, respiration, heart rate, blood pressure, and oxygen saturation were measured before and after treatment in both groups. Adverse events were recorded after treatment.

[0061] 1.6 Clinical efficacy evaluation criteria

[0062] Refer to the relevant content of the "Guiding Principles for Clinical Research of New Drugs of Traditional Chinese Medicine". Use the nimodipine method to calculate, with the formula: Syndrome integral effective rate = (pre-treatment integral post-treatment integral) / pre-treatment integral x 100%;

[0063] Clinical recovery: clinical symptoms disappear or basically disappear, with a decrease in symptom integral value ≥95% after treatment compared to before treatment;

[0064] Marked effectiveness: significant improvement in clinical symptoms, with a decrease in symptom integral value ≥70%, <95% after treatment compared to before treatment;

[0065] Effective: improvement in clinical symptoms, with a decrease in symptom integral value ≥30%, <70% after treatment compared to before treatment;

[0066] Ineffective: no improvement in clinical symptoms, with a decrease in symptom integral value <30% after treatment compared to before treatment.

[0067] Clinical total effective rate = (number of recovery cases + number of marked effectiveness cases + number of effective cases) / total number of cases x 100%.

[0068] 1.7 Statistical processing

[0069] Use SPSS 25.0 statistical software to process the data. If the measurement data meet the normal distribution and the variance is equal, use ±s indicates that the comparison between groups is made by two independent sample t test. The comparison between pre-treatment and post-treatment is made by paired t test. If not in accordance with normal distribution, the median (M) and quartile (P25, P75) are used, the comparison between groups is made by Mann- Whitney U test of non-parametric test, and the comparison within groups is made by Wilcoxon test of non-parametric test. The chi-square test is used for count data, and the frequency and percentage (n%) are described. P < 0.05 is considered to have a statistically significant difference.

[0070] 2. Results

[0071] 2.1 Comparison of total TCM symptom scores between the two groups before and after treatment

[0072] Before treatment, there was no significant difference in TCM syndrome scores between the two groups (P > 0.05); after treatment, the TCM syndrome scores of the two groups were lower than those before treatment, and the difference was statistically significant (P < 0.05). Among them, the improvement of TCM syndrome in the treatment group was better than that in the control group, and the difference was statistically significant (P < 0.05), see Table 2.

[0073]

[0074] 2.2 Comparison of clinical efficacy between the two groups after treatment

[0075] Among the 36 patients in the control group, 28 cases were effective, 8 cases were ineffective, and the total effective rate was 77.8%; among the 36 patients in the treatment group, 32 cases were effective, 2 cases were ineffective, and the total effective rate was 94.4%. The clinical total effective rate of the two groups was compared by chi-square test, and the difference was statistically significant (P < 0.05). See Table 3.

[0076]

[0077] Note: The two groups were compared by chi-square test, P < 0.05.

[0078] 2.3 SF-36 quality of life assessment before and after treatment in the two groups: Before treatment, there was no significant difference in the total score of SF-36 scale between the two groups (P > 0.05). Compared with before treatment, the total score of SF-36 scale in the two groups after treatment was significantly improved (P < 0.05), and the improvement degree in the treatment group was better than that in the control group, and the difference was statistically significant (P < 0.05). See Table 4.

[0079]

[0080] 2.4 Two groups of CRP, PCT, IL-6 levels before and after treatment: two groups of CRP, PCT, IL-6 levels before treatment, no significant difference (P>0.05); after treatment, two groups of CRP, PCT, IL-6 values were lower than before treatment (P<0.05), the treatment group was better than the control group in improving CRP, PCT, IL-6, the difference was statistically significant (P<0.05), see Table 5.

[0081]

[0082] 2.5 Comparison of FDP and DDi levels before and after treatment in two groups: there was no significant difference in FDP and DDi between the two groups before treatment (P>0.05); after treatment, the FDP and DDi values of the two groups were decreased compared with before treatment (P<0.05), the treatment group was better than the control group in improving FDP and DDi, the difference was statistically significant (P<0.05). See Table 6.

[0083]

[0084] 2.6 Comparison of recurrence rate after treatment in two groups: the recurrence of CAP was followed up for 1 month, 3 months and 6 months after treatment in two groups; after the total recurrence rate was calculated, the difference between the groups was compared, the recurrence rate of the control group was higher than that of the treatment group, the difference was statistically significant (P<0.05), see Table 7.

[0085]

[0086] 2.7 Safety evaluation of two groups during treatment: no obvious adverse reactions were found before and after treatment in two groups.

[0087] The above is only the preferred embodiment of the present application, it should be noted that for ordinary skilled in the art, without departing from the method of the present application, can also make a number of improvements and supplements, these improvements and supplements should also be considered as the protection scope of the present application.

Claims

1. An external use traditional Chinese medicine composition for treating community-acquired pneumonia recovery, characterized in that, The traditional Chinese medicine composition is made of raw medicinal materials in the following weight parts: 28-32 parts of raw Astragalus, 13-17 parts of fried Atractylodes, 10-14 parts of Angelica, 7-11 parts of Acorus, 4-8 parts of mugwort leaf, 7-11 parts of peach kernel, 4-8 parts of apricot kernel, 7-11 parts of Salvia miltiorrhiza, and 4-8 parts of Agastache.

2. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made of raw medicinal materials in the following weight parts: 29-31 parts of raw Astragalus, 14-16 parts of fried Atractylodes, 11-13 parts of Angelica, 8-10 parts of Acorus, 5-7 parts of mugwort leaf, 8-10 parts of peach kernel, 5-7 parts of apricot kernel, 8-10 parts of Salvia miltiorrhiza, and 5-7 parts of Agastache.

3. The traditional Chinese medicine composition according to claim 1, characterized in that, The traditional Chinese medicine composition is made of raw medicinal materials in the following weight parts: 30 parts of raw Astragalus, 15 parts of fried Atractylodes, 12 parts of Angelica, 9 parts of Acorus, 6 parts of mugwort leaf, 9 parts of peach kernel, 6 parts of apricot kernel, 9 parts of Salvia miltiorrhiza, and 6 parts of Agastache.

4. The traditional Chinese medicine composition according to any one of claims 1-3, characterized in that, The traditional Chinese medicine composition is a traditional Chinese medicine sachet.

5. A pharmaceutical composition for treating community-acquired pneumonia convalescence, characterized by, The pharmaceutical composition is composed of the traditional Chinese medicine composition according to any one of claims 1-3 and ambroxol hydrochloride.

6. Use of the traditional Chinese medicine composition according to any one of claims 1-3 in the preparation of a medicine for treating recovery stage of community-acquired pneumonia.

7. Use of the pharmaceutical composition according to claim 5 in the preparation of a medicine for treating recovery stage of community-acquired pneumonia.

Images